Eli Lilly and Company (LLY)
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
📈 **POSITIVE** • Medium confidence analysis (61%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (79%) **Content type:** Clinical